Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device company mergers

This article was originally published in The Gray Sheet

Executive Summary

Ruling Feb. 24 by the Federal Accounting Standards Board may slow down the pace of future consolidation, as acquiring firms will no longer be able to write off the cost of in-process research and development immediately. Under the new standard, all acquired in-process R&D "should be recognized as an asset and amortized over its useful economic life," FASB says. The policy is more broadly directed at goodwill and other purchased intangibles and addresses concerns that acquiring companies may essentially have been overstating earnings

You may also be interested in...



Cosmetics Weekly Trademark Review: 14 January 2020

Personal-care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps.

Cosmetics Weekly Trademark Review: 7 January 2020

Personal-care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps.

OTC Codeine Is 'Safe And Effective' – UK Industry Responds To BBC Exposé

Will the UK follow other countries and reverse-switch codeine to prescription-only status? British industry association, the PAGB, responds to a BBC documentary questioning the safety and efficacy of OTC codeine.
UsernamePublicRestriction

Register

MT011389

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel